Table 2.
Clinical studies for the treatment of cisplatin resistance in ovarian cancer.
Type of regimen | Therapy | Research progress | Treatment-related indicators |
Reference | ||
---|---|---|---|---|---|---|
Progression-free survival (months) | Overall survival (months) | Objective response rate (%) | ||||
Platinum alternative drugs | Carboplatin | In clinic | 4.8 | 127 | ||
Carboplatin, paclitaxel | In clinic | 12.5 | 7.4 | 126 | ||
Oxaliplatin | In clinic | 23.0 | 129 | |||
Paclitaxel | In clinic | 36.5 | 132 | |||
Paclitaxel, cisplatin | In clinic | 30.0 | 58.5 | 132 | ||
Paclitaxel, carboplatin | In clinic | 25.0 | 55.0 | 132 | ||
Topotecan | In clinic | 4.8 | 15.8 | 10.0 | 136 | |
Pemetrexed | Phase II clinical trial | 2.9 | 11.4 | 21 | 139 | |
Pemetrexed, carboplatin | Phase II clinical trial | 9.4 | 32.8 | 140 | ||
Gemcitabine | In clinic | 3.0 | 141 | |||
Topotecan, cisplatin | In clinic | 2.5 | 19.3 | 22.6 | 142 | |
PLD (pegylated liposomal doxorubicin) | In clinic | 3.7 | 143 | |||
PLD, olaratumab | Phase II clinical trial | 5.5 | 143 | |||
Anti-angiogenic drugs | Bevacizumab | In clinic | 4.4 | 145 | ||
Bevacizumab, gemcitabine | In clinic | 4 | 15.3 | 25.0 | 148 | |
Ramucirumab | Phase II clinical trial | 3.2 | 10.0 | 149 | ||
Apatinib | Phase Ⅳ clinical trial | 5.0 | 9.5 | 151 | ||
Apatinib, etoposide | Phase II clinical trial | 5.6 | 10.3 | 36.4 | 150 | |
PARP inhibitors | Olaparib | In clinic | 2.9 | 17.9 | 156 | |
Olaparib, PLD | Phase II clinical trial | 5.8 | 29.0 | 155 | ||
Niraparib | Phase Ⅲ clinical trial | 21.9 | 20.1 | 157 | ||
Rucaparib | Phase Ⅲ clinical trial | 16.6 | 158 | |||
Cell-cycle kinase inhibitors | Ribociclib | Phase I clinical trial | 11.4 | 79.3 | 163 | |
Abemaciclib | Phase Ⅲ clinical trial | 5.3 | 165 | |||
Abemaciclib, fulvestrant | Phase Ⅲ clinical trial | 16.9 | 46.7 | 165 | ||
Immunotherapy | Nivolumab | Phase II clinical trial | 3.5 | 20.0 | 172 | |
Nivolumab, ipilimumab | Phase II clinical trial | 3.9 | 28.1 | 31.4 | 174 | |
Pembrolizumab | Phase II clinical trial | 2.1 | 7.4 | 176 | ||
Pembrolizumab, niraparib | Phase I/II clinical trial | 18.0 | 177 | |||
Pembrolizumab, PLD | Phase II clinical trial | 19.0 | 180 | |||
Pembrolizumab, bevacizumab, cyclophosphamide | Phase II clinical trial | 10.0 | 47.5 | 181 | ||
Pembrolizumab, cisplatin, gemcitabine | Phase II clinical trial | 6.2 | 11.3 | 60.0 | 182 | |
Avelumab, PLD | Phase Ⅲ clinical trial | 3.7 | 15.7 | 183 | ||
Durvalumab, olaparib | Phase II clinical trial | 5.36 | 15.5 | 42.9 | 184 |